NCT06958796View on ClinicalTrials.gov

Strategic Help With Immunoglobulin to Enhance Protect Against Late Disease (CMV)

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

May 15, 2025

Primary Completion Date

December 30, 2027

Study Completion Date

May 31, 2028

Conditions
CytomegalovirusOrgan TransplantKidney Transplant; ComplicationsLiver Transplant ComplicationsSimultaneous Liver-Kidney Transplantation; Complications
Interventions
DRUG

Cytomegalovirus Immune Globulin Intravenous (Human) monthly for three months

The interventional arm will receive Cytomegalovirus Immune Globulin Intravenous (Human) monthly for three months as (150 mg/kg) for 3 consecutive months (Days 0, 28 and 56 +/- 3 days). The non-interventional arm will not receive any intervention.

Trial Locations (2)

75390

University of Texas Southwestern, Dallas

02114

Massachusetts General Hospital, Boston

All Listed Sponsors
collaborator

University of Texas Southwestern Medical Center

OTHER

collaborator

Kamada, Ltd.

INDUSTRY

lead

Camille N. Kotton, MD

OTHER